SG Talk

Conclusion
Two doses of the inactivated vaccine generate adequate humoral immune response in PD patients without any serious adverse events.

https://onlinelibrary.wiley.com/doi/10.1111/sdi.13049

2.4 The vaccine

Patients and healthy subjects received two doses of inactivated vaccine, CoronaVac®, which was developed by Sinovac Life Sciences (Beijing, China). This vaccine received authorization for emergency use in Turkey in January 2021. A 3 μg of the vaccine was administered as two doses, 28 days apart.

(09-01-2022, 08:54 AM)theold Wrote: [ -> ]Conclusion
Two doses of the inactivated vaccine generate adequate humoral immune response in PD patients without any serious adverse events.

https://onlinelibrary.wiley.com/doi/10.1111/sdi.13049

2.4 The vaccine

Patients and healthy subjects received two doses of inactivated vaccine, CoronaVac®, which was developed by Sinovac Life Sciences (Beijing, China). This vaccine received authorization for emergency use in Turkey in January 2021. A 3 μg of the vaccine was administered as two doses, 28 days apart.

What happened next......?

(09-01-2022, 09:03 AM)debono Wrote: [ -> ]What happened next......?

Weaker response has some benefits, suitable to those who want lower risks.
Weaker response does not mean lesser response as it teach whole piece of virus, 
it has border response as other parts of the virus are also identified.

You want lesser options available?

(09-01-2022, 09:17 AM)watchfirst9 Wrote: [ -> ]Weaker response has some benefits, suitable to those who want lower risks.
Weaker response does not mean lesser response as it teach whole piece of virus, 
it has border response as other parts of the virus are also identified.

You want lesser options available?

OIC, thanks for your reply.....